501 related articles for article (PubMed ID: 27502119)
1. Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod.
Ziemssen T; Kern R; Cornelissen C
BMC Neurol; 2016 Aug; 16():129. PubMed ID: 27502119
[TBL] [Abstract][Full Text] [Related]
2. The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice.
Ziemssen T; Kern R; Cornelissen C
BMC Neurol; 2015 Jun; 15():93. PubMed ID: 26084334
[TBL] [Abstract][Full Text] [Related]
3. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
[TBL] [Abstract][Full Text] [Related]
4. Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
Huhn K; Bayas A; Doerck S; Frank B; Gerbershagen K; Hellwig K; Kallmann B; Kleinschnitz C; Kleiter I; Lee DH; Limmroth V; Mäurer M; Meuth S; Rieckmann P; Ruck T; Gold R; Linker RA
J Neurol; 2018 Jul; 265(7):1521-1527. PubMed ID: 29696498
[TBL] [Abstract][Full Text] [Related]
5. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
[TBL] [Abstract][Full Text] [Related]
7. Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany.
Ziemssen T; Lang M; Schmidt S; Albrecht H; Klotz L; Haas J; Lassek C; Lang S; Winkelmann VE; Ettle B; Schulze-Topphoff U;
J Neurol; 2022 Jun; 269(6):3276-3285. PubMed ID: 34982201
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis.
Braune S; Lang M; Bergmann A;
J Neurol; 2016 Feb; 263(2):327-333. PubMed ID: 26645389
[TBL] [Abstract][Full Text] [Related]
9. Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?
Fernández Ó
Mult Scler Relat Disord; 2017 Oct; 17():75-83. PubMed ID: 29055479
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis.
Derfuss T; Bergvall NK; Sfikas N; Tomic DL
Curr Med Res Opin; 2015; 31(9):1687-91. PubMed ID: 26121423
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice].
Alcala-Vicente C; Perez-Miralles FC; Gascon-Gimenez F; Bosca-Blasco I; Navarre-Gimeno A; Coret-Ferrer F; Casanova-Estruch B
Rev Neurol; 2017 May; 64(10):445-453. PubMed ID: 28497440
[TBL] [Abstract][Full Text] [Related]
12. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East.
Achiron A; Aref H; Inshasi J; Harb M; Alroughani R; Bijarnia M; Cooke K; Yuksel O
BMC Neurol; 2017 Aug; 17(1):150. PubMed ID: 28784108
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA.
Ziemssen T; Lang M; Tackenberg B; Schmidt S; Albrecht H; Klotz L; Haas J; Lassek C; Medin J; Cornelissen C;
Neurotherapeutics; 2018 Jan; 15(1):190-199. PubMed ID: 29274026
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
[TBL] [Abstract][Full Text] [Related]
16. Real-world effectiveness of fingolimod in Polish group of patients with relapsing-remitting multiple sclerosis.
Walczak A; Kurkowska-Jastrzebska I; Zakrzewska-Pniewska B; Dorobek M; Brola W; Zajdel R; Bartosik-Psujek H; Stasiolek M; Kulakowska A; Rusek S; Tutaj A; Glabinski A; Wlodek A; Kochanowski J; Ciach A; Siger M; Kurowska K; Wicha W; Nojszewska M; Podlecka-Pietowska A; Czajka A; Kapica-Topczewska K; Bielecki B; Maciagowska-Terela M; Stepien A
Clin Neurol Neurosurg; 2019 Sep; 184():105453. PubMed ID: 31376776
[TBL] [Abstract][Full Text] [Related]
17. Fingolimod for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
Algahtani H; Shirah B; Al Malik Y; Meftah I
Clin Neuropharmacol; 2020; 43(2):35-38. PubMed ID: 32106137
[TBL] [Abstract][Full Text] [Related]
18. Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis.
Preziosa P; Rocca MA; Riccitelli GC; Moiola L; Storelli L; Rodegher M; Comi G; Signori A; Falini A; Filippi M
Neurotherapeutics; 2020 Jan; 17(1):208-217. PubMed ID: 31452082
[TBL] [Abstract][Full Text] [Related]
19. Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).
Klotz L; Grützke B; Eveslage M; Deppe M; Gross CC; Kirstein L; Posevitz-Fejfar A; Schneider-Hohendorf T; Schwab N; Meuth SG; Wiendl H
BMC Neurol; 2015 Jun; 15():96. PubMed ID: 26099927
[TBL] [Abstract][Full Text] [Related]
20. Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study.
Tichá V; Kodým R; Počíková Z; Kadlecová P
Clin Drug Investig; 2017 Feb; 37(2):175-186. PubMed ID: 27785735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]